- likes
- 145
- comments
- 7
Post
Guided by our Mission to deliver the greatest possible impact to people through mRNA medicines, Moderna remained focused in 2025 on operational execution, scientific progress and disciplined financial management - navigating a difficult environment while strengthening our foundation for long-term growth. With three approved commercial products, continued pipeline momentum across infectious diseases, oncology and rare diseases, an extraordinary team and a global manufacturing network, we are entering 2026 positioned to deliver the next era of growth and innovation in mRNA medicines. Read more in our CEO Stéphane Bancel’s annual letter to shareholders: https://lnkd.in/eSMyTkTn